|
Active substance |
Patisiran-LNP |
|
Holder |
Alnylam Netherlands |
|
Status |
Closed |
|
Indication |
hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
|
Public documents |
|
|
Last update |
29/11/2019 |
Onpattro
Last updated on 03/04/2024